Pulse Biosciences Must Confirm Its AFib Pivotal Trial Finished Early As Cash Burn Climbs

When Pulse Biosciences reports third-quarter results after the close on November 5, the income statement will matter far less than one date on the calendar. Last quarter, management said its pivotal Nanopulse AF study of a cardiac catheter for atrial fibrillation would finish enrolling in early October. That is well ahead of the original end-of-2026 target, and that deadline has now passed. This report is the first chance to learn whether the company actually crossed the finish line. The stock has rallied more than 40% since the last report on the strength of that promise.

The Street's numbers barely register next to that question. Analysts expect a loss of $0.35 per share, roughly in line with last quarter's $0.36 and wider than the $0.29 loss a year ago. Revenue is pegged at about $500,000. That works out to growth of more than 480% from a tiny base, but it is only a modest step up from the $434,000 booked last quarter. Pulse has offered no formal financial guidance, so there is no range to measure the consensus against. Revenue remains immaterial, and cost of goods has been running close to sales. A beat or miss on either line should not move the thesis much.

What will matter is evidence that last quarter's clinical momentum held up. On the prior call, management described enrollment running fast enough that it expected to activate fewer than the 30 sites it was allowed. Some centers were performing five to seven cases a day, and ablation times were running seven to eight minutes. The company also raised the enrollment target from 145 to 164 patients after loosening inclusion criteria tied to antiarrhythmic drugs. A clean confirmation would validate that story: full enrollment at the larger target, completed on time, plus a clear timeline for follow-up and data readout. Silence or a slip into later in the quarter would challenge the narrative that this program is outrunning expectations. Investors should also look for confirmation that the European CE mark submission is still on track for the second half of 2026. That filing rests on feasibility data showing roughly 90% one-year freedom from arrhythmia. Updates on the thyroid business would help too, including progress on the expanded 100-patient study and the new Klayman Thyroid Center partnership.

The cost side is the counterweight. Non-GAAP operating expenses climbed from $17.4 million to $20.5 million last quarter, and operating cash burn rose to $18.7 million. A flat per-share loss estimate can mask a larger dollar loss when at-the-market stock sales increase the share count. The more telling figures will be absolute spending and the cash balance, which stood at $101.6 million in June after an ATM raise of about $57.5 million. Rising costs as enrollment wraps up would be understandable. A burn rate that keeps rising after the trial's most intensive phase would raise sharper questions about how often Pulse must tap its new $75 million ATM facility.

The market has priced in a good deal of optimism. The stock beat the S&P 500 by nearly 41 percentage points over the period and trades at $53.20, far above its 200-day moving average near $30.68. Its post-earnings range of $37.40 to $58.90 sits wholly above the prior quarter's band. The shares remain about 10% below that recent high, so this is not a breakout setup. Sentiment readings edged up only slightly, from 8% to 10% bullish, which suggests enthusiasm is concentrated in the price rather than in broad conviction.

The central test is simple. If Pulse confirms that pivotal enrollment closed on schedule and lays out a credible path to data and regulatory filings, the clinical-execution story that powered the rally stays intact. If it reveals delays alongside ever-higher spending, a stock that has already run hard may have little cushion.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.